Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer

Inclusion Criteria: * According to FIGO criteria, participants must have a histological diagnosis of high-grade serous or endometrioid carcinoma, or high-grade serous or endometrioid predominantly ovarian, fallopian tube cancer, or stage III or IV primary peritoneal carcinoma * Inoperable stage III and IV patients; All stage III and IV patients who can accept initial or intermittent tumor reduction surgery, regardless of the residual lesion status after surgery * Patients who had undergone abdominal chemotherapy; All participants must undergo 6 and 9 cycles of platinum-based therapy; Participants were required to receive 2 cycles of postoperative platinum therapy following interphase tumor reduction surgery; Participants had to be assessed by a physician for complete response (CR) or partial response (PR) after 3 cycles of treatment; Participants had to have cancer antigen 125 (CA-125) within the normal range or ca-125 decreased by more than 90%(%) to be stable during their first-line therapy * All participants must agree to be tested for central tumor BRCA * Fertile participants must have a negative serum or urine pregnancy test (human chorionic gonadotropin \[hCG\]) within 7 days of receiving the first dose of study treatment. Exclusion Criteria: * Participants had epithelial ovarian carcinosarcoma or mucinous or clear cell subtypes of undifferentiated ovarian cancer * The participants had already undergone more than two tumor-reduction surgeries for the study disease * Participants became pregnant or lactated or expected to become pregnant during study treatment and 180 days after the last dose of study treatment * Participants were known to be allergic to the ingredients or excipients of the study drug * Participants had previously been treated with a known PARP inhibitor or had participated in any treatment group that included the use of a known PARP inhibitor * Participants received bevacizumab maintenance therapy * Subjects received investigational therapy within 4 weeks or at intervals not exceeding 5 investigational drug half-lives, whichever is longer, prior to the study's first scheduled dosing date * Participants had known grade 3 anemia, neutropenia or thrombocytopenia that persisted due to prior chemotherapy. 4 weeks； * Throughout the study treatment period, participants were treated with conditions (such as transfusion-dependent anemia or thrombocytopenia) or laboratory abnormalities that could confound study results or interfere with their participation, including: * Participants received blood transfusions (platelets or red blood cells) within 2 weeks of the first dose of study treatment * Participants received colony stimulating factor (e.g., granulocyte-colony-stimulating factor \[G-CSF\] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment; * Participants had been diagnosed and/or treated for invasive cancer less than 5 years prior to enrollment